

# Michael R Harrison

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8989246/publications.pdf>

Version: 2024-02-01

83  
papers

4,890  
citations

172457

29  
h-index

98798

67  
g-index

84  
all docs

84  
docs citations

84  
times ranked

7117  
citing authors

#	ARTICLE	IF	CITATIONS
1	Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1430-1437.	1.6	914
2	Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1370-1385.	10.7	594
3	Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 804-834.	4.9	443
4	Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 931-945.	10.7	337
5	Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 5461-5471.	7.0	234
6	Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 1886-1890.	7.0	189
7	NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1278-1285.	4.9	185
8	Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 78-86.	7.0	154
9	Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. <i>Lancet Oncology</i> , The, 2019, 20, 581-590.	10.7	124
10	Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 872-882.	10.7	122
11	Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. <i>Cancer Management and Research</i> , 2013, 5, 1.	1.9	101
12	A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal <sup>®</sup> dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). <i>Investigational New Drugs</i> , 2011, 29, 1465-1474.	2.6	96
13	Novel therapies are changing treatment paradigms in metastatic prostate cancer. <i>Journal of Hematology and Oncology</i> , 2020, 13, 144.	17.0	80
14	Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins. <i>Clinical Advances in Hematology and Oncology</i> , 2009, 7, 54-64.	0.3	73
15	Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 3140-3148.	1.6	72
16	Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice. <i>Journal of Oncology Practice</i> , 2015, 11, 491-497.	2.5	67
17	<i>LRP1B</i> mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types. , 2021, 9, e001792.		63
18	Pharmacodynamic Study Using FLT PET/CT in Patients with Renal Cell Cancer and Other Solid Malignancies Treated with Sunitinib Malate. <i>Clinical Cancer Research</i> , 2011, 17, 7634-7644.	7.0	62

#	ARTICLE	IF	CITATIONS
19	Body mass index and all-cause mortality in heart failure patients with normal and reduced ventricular ejection fraction: a doseâ€“response meta-analysis. <i>Clinical Research in Cardiology</i> , 2019, 108, 119-132.	3.3	62
20	A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 883-892.	2.3	59
21	Pembrolizumab in men with heavily treated metastatic castrateâ€“resistant prostate cancer. <i>Cancer Medicine</i> , 2019, 8, 4644-4655.	2.8	55
22	Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 1285-1301.	3.0	42
23	Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial. , 2022, 10, e003844.		42
24	Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2021, 7, 1815.	7.1	40
25	Novel Immunotherapeutic Strategies in Development for Renal Cell Carcinoma. <i>European Urology</i> , 2013, 63, 881-889.	1.9	39
26	Development of a Novel c-METâ€“Based CTC Detection Platform. <i>Molecular Cancer Research</i> , 2016, 14, 539-547.	3.4	37
27	Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 392-399.	1.9	36
28	Rowâ€“spacing and Seeding Rate Effects on Glyphosateâ€“Resistant Soybean for Midâ€“Atlantic Production Systems. <i>Agronomy Journal</i> , 2004, 96, 1029-1038.	1.8	32
29	Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC). <i>Cancer</i> , 2021, 127, 2204-2212.	4.1	32
30	Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e513-e521.	1.9	31
31	â€œReal Worldâ€“Treatment of Metastatic Renal Cell Carcinoma in a Joint Community-Academic Cohort: Progression-Free Survival Over Three Lines of Therapy. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 441-450.	1.9	29
32	Real-World Outcomes in Metastatic Renal Cell Carcinoma: Insights From a Joint Community-Academic Registry. <i>Journal of Oncology Practice</i> , 2014, 10, e63-e72.	2.5	25
33	Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrateâ€“resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 418-424.	1.6	24
34	Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 83-93.	1.6	24
35	A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinumâ€“resistant metastatic urothelial cancer. <i>Cancer</i> , 2020, 126, 4485-4497.	4.1	24
36	A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrateâ€“resistant prostate cancer. <i>Cancer</i> , 2021, 127, 2954-2965.	4.1	21

#	ARTICLE	IF	CITATIONS
37	Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study. , 2020, 8, e000538.		19
38	Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial. European Urology Oncology, 2021, 4, 948-954.	5.4	18
39	Deferred Systemic Therapy in Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2015, 13, e159-e166.	1.9	17
40	Platinum sensitivity in metastatic prostate cancer: does histology matter?. Prostate Cancer and Prostatic Diseases, 2018, 21, 92-99.	3.9	17
41	Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma. Biomarker Research, 2021, 9, 80.	6.8	16
42	Treatment-related neuroendocrine prostate cancer resulting in Cushing's syndrome. International Journal of Urology, 2016, 23, 1038-1041.	1.0	15
43	Combination antiangiogenic tyrosine kinase inhibition and anti-EPD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. Cancer Medicine, 2021, 10, 2341-2349.	2.8	15
44	Physical activity patterns and associations with health-related quality of life in bladder cancer survivors. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 540.e1-540.e6.	1.6	14
45	Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients. Prostate Cancer and Prostatic Diseases, 2019, 22, 588-592.	3.9	14
46	Activity of Single-Agent Bevacizumab in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors. Clinical Genitourinary Cancer, 2013, 11, 45-50.	1.9	13
47	A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, 25, 762-769.	3.9	13
48	Pazopanib for the Treatment of Patients with Advanced Renal Cell Carcinoma. Clinical Medicine Insights: Oncology, 2010, 4, CMO.S4088.	1.3	12
49	Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract: an evidence-based review of safety, efficacy, and place in therapy. Core Evidence, 2018, Volume 13, 1-12.	4.7	10
50	Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 109, 1271-1278.	0.8	10
51	Reversal of PSA progression on abiraterone acetate through the administration with food in men with metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2015, 18, 161-166.	3.9	9
52	Better Late than Early: FDG-PET Imaging in Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2011, 17, 5841-5843.	7.0	8
53	Use of "Real-World" data to describe adverse events during the treatment of metastatic renal cell carcinoma in routine clinical practice. Medical Oncology, 2014, 31, 156.	2.5	8
54	Dietary patterns and health-related quality of life in bladder cancer survivors. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 469.e21-469.e29.	1.6	7

#	ARTICLE	IF	CITATIONS
55	How we treat brain metastases in metastatic renal cell carcinoma. <i>Clinical Advances in Hematology and Oncology</i> , 2018, 16, 110-114.	0.3	7
56	Pharmacotherapy Options in Advanced Renal Cell Carcinoma: What Role for Pazopanib?. <i>Clinical Medicine Insights: Oncology</i> , 2011, 5, CMO.S6087.	1.3	6
57	Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial. <i>Prostate</i> , 2017, 77, 385-395.	2.3	6
58	Optimizing the Efficiency and Quality of Sipuleucel-T Delivery in an Academic Institution. <i>Clinical Journal of Oncology Nursing</i> , 2015, 19, 297-303.	0.6	5
59	High rates of venous thromboembolic events in patients undergoing systemic therapy for urothelial carcinoma: A systematic review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 407-414.	1.6	5
60	Design and Rationale of the Metastatic Renal Cell Carcinoma (MaRCC) Registry: A Prospective Academic and Community-Based Study of Patients With Metastatic Renal Cell Cancer. <i>Cancer Investigation</i> , 2017, 35, 333-344.	1.3	5
61	Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 330-337.	0.9	5
62	Body composition, physical function and quality of life in healthy men and across different stages of prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 725-732.	3.9	5
63	Response to antiangiogenesis therapy in a patient with advanced adult-type testicular granulosa cell tumor. <i>Oncology</i> , 2009, 23, 792-5.	0.5	5
64	Feasibility of home-based exercise training in men with metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, , .	3.9	5
65	Exercise as Treatment for Androgen Deprivation Therapyâ€‘Associated Physical Dysfunction: Ready for Prime Time?. <i>European Urology</i> , 2014, 65, 873-874.	1.9	4
66	A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 1-10.	1.9	4
67	A randomized controlled trial comparing changes in fitness with or without supervised exercise in patients initiated on enzalutamide and androgen deprivation therapy for non-metastatic castration-sensitive prostate cancer (EXTEND). <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 58-64.	3.9	4
68	The feasibility of finger prick autologous blood (FAB) as a novel treatment for severe dry eye disease (DED): protocol for a randomised controlled trial. <i>BMJ Open</i> , 2018, 8, e026770.	1.9	3
69	Real-world systemic therapy utilization in Medicare patients with locally advanced or metastatic urothelial carcinoma diagnosed between 2008 and 2012. <i>Journal of Geriatric Oncology</i> , 2021, 12, 298-304.	1.0	3
70	Metastatic Urothelial Carcinoma from Transplanted Kidney with Complete Response to an Immune Checkpoint Inhibitor. <i>Case Reports in Urology</i> , 2020, 2020, 1-5.	0.3	3
71	Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. <i>European Urology Open Science</i> , 2021, 34, 70-78.	0.4	3
72	Resistance exercise training in patients with genitourinary cancers to mitigate treatment-related skeletal muscle loss. <i>Clinical Advances in Hematology and Oncology</i> , 2016, 14, 436-46.	0.3	3

#	ARTICLE	IF	CITATIONS
73	Burden of Disease Matters When It Comes to Systemic Therapy for Prostate Cancer. <i>European Urology</i> , 2015, 67, 448-450.	1.9	2
74	Look and You Will Find It: Practical Considerations for Improving Multidisciplinary Management of Androgen-Deprivation Therapyâ€“Induced Cardiometabolic Toxicity. <i>Journal of Oncology Practice</i> , 2018, 14, 591-593.	2.5	2
75	Referral and adjuvant treatment patterns after nephrectomy in highâ€“risk locoregional renal cell carcinoma. <i>Cancer Medicine</i> , 2021, 10, 8891-8898.	2.8	2
76	Markers of inflammation are associated with clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab. , 2015, 3, .		1
77	Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castrationâ€“resistant prostate cancer. <i>Prostate</i> , 2019, 79, 1752-1761.	2.3	1
78	PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 509-513.	1.9	1
79	Treatment selection in metastatic renal cell carcinoma: more confusion or a path forward?. <i>Clinical Advances in Hematology and Oncology</i> , 2014, 12, 163-71.	0.3	1
80	Real-World Data from a Metastatic Renal Cell Carcinoma Community-Academic Registry: Comparative Outcomes of Progression Free Survival and Overall Survival. <i>Kidney Cancer</i> , 2019, 3, 133-140.	0.4	0
81	Urologic Malignancies. , 2019, , 115-133.		0
82	BODY COMPOSITION, PHYSICAL FUNCTION AND QUALITY OF LIFE ACROSS DIFFERENT STAGES OF PROSTATE CANCER: A CROSS-SECTIONAL ANALYSIS. <i>Medicine and Science in Sports and Exercise</i> , 2020, 52, 981-981.	0.4	0
83	The Fetus at Surgery. , 0, , 607-616.		0